ACAD
39.46
-0.39
-0.98%
AEMD
3.881
+0.001
+0.0309%
APRI
2.945
-0.205
-6.5206%
ARNA
1.53
-0.04
-2.55%
ATEC
3.41
-0.16
-4.48%
CNAT
4.86
-0.19
-3.76%
CRXM
0.23
+0.02
+7.23%
CYTX
1.73
-0.02
-1.14%
DXCM
77.805
-1.405
-1.774%
GNMK
11.36
-0.23
-1.98%
HALO
12.71
-0.16
-1.24%
ILMN
167.782
+0.962
+0.577%
INNV
0.16
0.00
+3.23%
INO
7.01
-0.16
-2.23%
ISCO
1.15
+0.05
+4.55%
ISIS
57.56
0.00
0.00%
LGND
106.33
-1.05
-0.98%
LPTN
2.93
0.00
0.00%
MBVX
3
-0.09
-2.91%
MEIP
1.69
-0.02
-1.17%
MNOV
6.49
+0.04
+0.62%
MRTX
5.65
-0.3
-5.04%
MSTX
0.114
-0.004
-3.4043%
NBIX
44.63
-0.5
-1.11%
NUVA
74.93
-0.04
-0.05%
ONCS
1.44
-0.02
-1.37%
ONVO
3.185
-0.015
-0.469%
OREX
4.485
-0.175
-3.755%
OTIC
15
-0.55
-3.54%
QDEL
21.5
-0.39
-1.78%
RCPT
231.96
0.00
0.00%
RGLS
1
-0.05
-4.76%
RMD
71.98
-0.04
-0.06%
SPHS
2.66
+0.01
+0.38%
SRNE
5.225
-0.125
-2.336%
TROV
1.975
-0.025
-1.250%
VICL
2.18
-0.01
-0.46%
VOLC
18
0.00
0.00%
ZGNX
10.451
-0.15
-1.4104%
ACAD
39.46
-0.39
-0.98%
AEMD
3.881
+0.001
+0.0309%
APRI
2.945
-0.205
-6.5206%
ARNA
1.53
-0.04
-2.55%
ATEC
3.41
-0.16
-4.48%
CNAT
4.86
-0.19
-3.76%
CRXM
0.23
+0.02
+7.23%
CYTX
1.73
-0.02
-1.14%
DXCM
77.805
-1.405
-1.774%
GNMK
11.36
-0.23
-1.98%
HALO
12.71
-0.16
-1.24%
ILMN
167.782
+0.962
+0.577%
INNV
0.16
0.00
+3.23%
INO
7.01
-0.16
-2.23%
ISCO
1.15
+0.05
+4.55%
ISIS
57.56
0.00
0.00%
LGND
106.33
-1.05
-0.98%
LPTN
2.93
0.00
0.00%
MBVX
3
-0.09
-2.91%
MEIP
1.69
-0.02
-1.17%
MNOV
6.49
+0.04
+0.62%
MRTX
5.65
-0.3
-5.04%
MSTX
0.114
-0.004
-3.4043%
NBIX
44.63
-0.5
-1.11%
NUVA
74.93
-0.04
-0.05%
ONCS
1.44
-0.02
-1.37%
ONVO
3.185
-0.015
-0.469%
OREX
4.485
-0.175
-3.755%
OTIC
15
-0.55
-3.54%
QDEL
21.5
-0.39
-1.78%
RCPT
231.96
0.00
0.00%
RGLS
1
-0.05
-4.76%
RMD
71.98
-0.04
-0.06%
SPHS
2.66
+0.01
+0.38%
SRNE
5.225
-0.125
-2.336%
TROV
1.975
-0.025
-1.250%
VICL
2.18
-0.01
-0.46%
VOLC
18
0.00
0.00%
ZGNX
10.451
-0.15
-1.4104%
Home » Archive by Category

Syndication

Accounting & Office Coordinator – Mesa Biotech – San Diego, CA

February 22, 2017 – 12:38 pm

Familiar with QuickBooks data entry. The Accounting and Administration Assistant position is an entry-level position in our Accounting and Administration… $15 – $20 an hourFrom Indeed – Wed, 22 Feb 2017 20:38:39 GMT – View all San Diego jobs

Sr. Manufacturing Bulk Operator (San Diego)

February 22, 2017 – 12:30 pm

At Pacira Pharmaceuticals, controlling postsurgical pain is the key to improving patient outcomes. Our in-depth knowledge of the needs of the postsurgical pain market, coupled with our passion for delivering improved patient care, drives our commitme […

Research Associate (Kearny Mesa)

February 22, 2017 – 10:49 am

RESEARCH ASSOCIATE
A local preclinical Contract Research Organization located in Kearny Mesa is seeking candidate for a Research Associate. The Research Associate is responsible for the scheduling and conduct of in-vivo studies involving the testing […

Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M

February 22, 2017 – 9:24 am

PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The company,…

[[Click headline to continue reading.]]

PrimeVax Immuno-Oncology to Present at Biocom Global Life Science Partnering Conference

February 22, 2017 – 8:00 am

Cancer Immunotherapy Company to Discuss Clinical Translation of PV-001 Dengue/Dendritic Cell Treatment

SAN DIEGO, Feb. 22, 2017 /PRNewswire/ — PrimeVax Immuno-Oncology, Inc. announced today its CEO, Tony Chen, will be presenting at the Annual Biocom Global Life Science Partnering Conference.  The presentation will take place on March 2, at 11:15 AM, at the Torrey Pines Lodge, in San Diego. 

“We are thankful to the organizers at Biocom who have chosen our company, amongst numerous others, to present at this international symposium of biotechnology companies, investors, and clinical researchers,” said Mr. Chen. “In contrast to conferences in previous years, there is an increase in the number of cancer immunotherapy companies presenting. This trend reflects the excitement we observe in the industry where new methods are being tried to fight cancer.”

PrimeVax takes a unique approach to treating cancer by combining virus-induced immune stimulation and dendritic cell therapy.  A description of the PrimeVax approach was recently published in the peer-reviewed literature by the company management1.

“With the clinical implementation of various immunotherapeutic strategies, it is becoming more and more apparent that we need to activate multiple arms of the immune system at the same time,” said Santosh Kesari, MD, PhD, Scientific Co-Founder of PrimeVax and Chair of Neurosciences and Neurotherapeutics at the John Wayne Cancer Institute and Pacific Neuroscience Institute. “We are very excited about the progress that Mr. Chen has made in advancing this technology, and I look forward to helping patients suffering from deadly cancers such as melanoma and glioblastoma.”

About Us

PrimeVax Immuno-Oncology, Inc. is focused on development of personalized immunotherapy by leveraging its PV-001 platform.  The platform enables PrimeVax to develop a 1 time 1 week cancer treatment schedule for many cancer types agnostic of tumor mutation characteristics. PV-001 leverages the body’s innate and adaptive immune responses simultaneously to trigger activation of T cells, NK cells, and other immunotherapeutic effects. The Company was founded in 2015 and will engage in human clinical trials in 2017. Initial indications to be targeted are metastatic melanoma, triple negative breast cancer, and glioblastoma.

Contact:   
PrimeVax Immuno-Oncology, Inc.    
Tony Chen  
CEO  
Tony.Chen@PrimeVax.com  
PrimeVax Immuno-Oncology

1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307212/pdf/12967_2014_Article_349.pdf

 

SOURCE PrimeVax Immuno-Oncology, Inc.

Aethlon Medical Reports Results of Cytomegalovirus, Epstein-Barr and Herpes Simplex Virus Studies

February 22, 2017 – 6:25 am

SAN DIEGO, Feb. 22, 2017 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), today reported the results of a study that validated the ability of the Aethlon Hemopurifier® to capture latent viral pathogens that are associated with increased mortality in immune-suppressed sepsis patients and also contribute to organ rejection in transplant patients.  

The objective of the study was to validate the in vitro capture of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. The Company also reported that it conducted a related study to identify the presence of each of these viruses in blood samples obtained from organ transplant patients who were also suffering from sepsis.

The overall goal of the study was to further reinforce the broad-spectrum capability of the Hemopurifier to capture infectious viral pathogens. CMV, EBV and HSV1 are among the most common latent viruses, which can become life threatening when reactivated in immune compromised individuals.  The Hemopurifier® is a first-in-class medical technology currently being advanced in FDA approved studies.  In previous studies, the device has been demonstrated to capture a wide range of bioterror related, pandemic and chronic infectious viruses.  The Company believes that the Hemopurifier can fulfill the broad-spectrum medical countermeasure goal of the U.S. Department of Health and Human Services (HHS) 2016 Public Health Emergency Medical Countermeasure Enterprise (PHEMCE), which is directed toward bioterror, pandemic threats and other pathogens that are not well addressed with disease-specific drug therapies.

In the latent viral pathogen study, a 72% reduction of HSV1 from human blood serum was observed in six hours of Hemopurifier® application.  Studies involving EBV and CMV were also conducted, showing a reduction of 77% and 88%, respectively, during the six-hour applications.  In all three sets of experiments, controls consisting of blood serum samples not subjected to the Hemopurifier® did not exhibit a significant reduction in infectious virus.  This study incorporated the use of small-scale Hemopurifier® devices that model virus capture from small volumes of human blood serum.  The quantification of viral elimination was performed through plaque assays, which account for infectious virus capture.  A study to demonstrate the simultaneous capture of all three viruses is now being conducted.

Aethlon researchers also reported on the incidence of HSV1 and CMV infection in blood samples of 15 subjects who had been admitted into intensive care.  Twelve (12) of these subjects were organ transplant recipients. The researchers identified that 8 of the 15 subjects (53%) had reactivated CMV infection, while seven (7) of the subjects (47%) had reactivated HSV1 infection. Six (6) of the 15 subjects (40%) were co-infected with both CMV and HSV1.  Seven (7) of the 15 subjects had received antiviral drug medication.  Of these, three (3) subjects still had a presence of CMV, of which two (2) subjects were also co-infected with HSV1.  The presence of EBV was not identified in any of the subjects. The attending clinical staff had also determined that 14 of the 15 subjects were suffering from sepsis. The tested samples were provided through collaboration with the University of Pittsburgh Medical Center.   

The reactivation of latent viral pathogens is a common occurrence in septic patients.  In a published 2014 report by Walton et al. entitled Reactivation of Multiple Viruses in Patients with Sepsis, the incidence of CMV, EBV and HSV reactivation was examined in blood and/or plasma samples from critically ill septic patients. The results showed the incidence of CMV to be 24.2% (86/356). EBV was reported in 53.2% (287/539) of the patients and the incidence of HSV was 14.1% (76/538).  This study was conducted by The Washington University School of Medicine in Saint Louis.

Beyond its previously validated ability to capture bioterror related, pandemic and chronic infectious viruses, the Aethlon Hemopurifier® also provides a candidate strategy to address CMV, EBV, HSV1 and other latent viral infections that can be life threatening to immune-suppressed sepsis patients and organ transplant recipients.  

About Cytomegalovirus (CMV)

The incidence of cytomegalovirus in the U.S. population is greater than 60%, with prevalence increasing up to 90% for elderly individuals.  Much like HSV1 and EBV, CMV is a dangerous pathogen for individuals with compromised immune systems.  Beyond sepsis, individuals with high-risk CMV infections include solid organ transplant recipients, hematopoietic cell transplant recipients, those with HIV infection, cancer patients, and recipients of immune-modulating drugs. 

About Epstein – Barr Virus (EBV)

Epstein-Barr virus is extremely prevalent in the U.S., affecting 80%-90% of the country’s population.  Beyond the potential role of EBV in sepsis, immune compromised individuals face an increased risk of stem cell and solid organ transplant rejections. EBV infected individuals are also at risk for Burkitt’s lymphoma and nasopharyngeal carcinoma.  HIV-infected individuals who are co-infected with EBV are at risk for a wide range of severe disease ailments.

About Herpes Simplex Virus 1 and 2 (HSV1/HSV2)

Estimates for the incidence of HSV1 and HSV2 in the U.S. are approximately 65% and 17%, respectively.  Common physical symptoms include minor cold sores and lesions. However, HSV1 can cause severe ailments in immunocompromised patients.  Beyond the potential role of HSV1 in sepsis, herpetic infections can cause progressive and persistent esophagitis, colitis, perianal ulcers, and pneumonia. HSV1 can also cause central nervous system infections such as encephalitis and meningitis.  Neonatal HSV1 infection can contribute to infant morbidity and mortality.

About Aethlon Medical

Aethlon Medical (Nasdaq: AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer.  To augment the body’s natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.  Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “will,” “projections,” “estimate,” or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company’s ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company’s clinical programs or provide market clearance of the Company’s products, including any products relating to the Zika or MERS-CoV viruses or relating to sepsis, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company’s proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2016, and in the Company’s other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:

Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc. 
858-489-7800 extension 3300
Jfrakes@aethlonmedical.com

 

SOURCE Aethlon Medical, Inc.

Oncternal Closes $18.4 Million Series B Financing

February 22, 2017 – 5:30 am

Proceeds support advancement of clinical development programs and early stage pipeline

SAN DIEGO, Feb. 22, 2017 /PRNewswire/ — Oncternal Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies for both rare and common malignancies, today announced the closing of an $18.4 million Series B financing. The company intends to use the proceeds to further clinical development programs for cirmtuzumab and TK216, and to advance preclinical development of a new ROR1-targeted antibody-drug conjugate (ADC) program.

Cirmtuzumab is a first-in-class anti-ROR1 monoclonal antibody being developed to treat patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Research has shown that ROR1 expression identifies cancer stem cells in a number of hematologic malignancies and solid tumors, and that certain antibodies against ROR1 inhibit malignant behavior. Initial findings from the ongoing Phase 1a clinical trial in patients with relapsed or refractory CLL, including signs of pharmacological activity and prolonged progression-free survival, were presented at the American Society of Hematology Meeting in December 2016.

TK216 is a first-in-class small molecule that inhibits the biological activity of ets-family transcription factor oncoproteins in a variety of tumor types, inhibiting cancer cell growth and tumor formation in nonclinical models. In Ewing sarcoma, TK216 is designed to target a fusion protein that causes the disease. A Phase 1 clinical trial in patients with relapsed or refractory Ewing sarcoma is currently underway. Oncternal has received Orphan Drug Designation and Fast Track status from the U.S. Food and Drug Administration (FDA) for TK216 in Ewing sarcoma and will be eligible to receive a Rare Pediatric Disease Priority Review Voucher if approved for this indication.

Oncternal is also investigating the potential of ROR1-targeted ADCs. Preclinical models show that upon binding, ROR1 antibodies such as cirmtuzumab are rapidly internalized and traffic inside the cell in a manner that is ideal for delivering a cytotoxic payload. Oncternal is generating and evaluating a series of ROR1-targeted ADCs utilizing several different toxic payloads, linkers and antibody conjugation chemistry. Preclinical evaluation of these candidates will continue during 2017.

“We are extremely pleased with the rapid progress we have made in our clinical development programs since Oncternal was formed just nine months ago, and we appreciate the strong support of our shareholders and new investors,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. “We have reached the top dose group in our Phase 1a clinical trial of cirmtuzumab without safety issues and with evidence of pharmacological activity. We are preparing to launch a Phase 1b/2 clinical trial of cirmtuzumab combined with ibrutinib as treatment for patients with CLL and MCL. With TK216, we have progressed through four dose levels in our Phase 1a study for patients with Ewing sarcoma without dose limiting toxicity, and have new nonclinical data to support development of TK216 for patients with hematologic malignancies. Additionally, we have initiated an anti-ROR1 ADC program and are testing product candidates from the program to add to our development pipeline.”

About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers by focusing on targets that are uniquely expressed within cancer cells. The company is leveraging its scientific and development expertise, as well as academic collaborations, to rapidly advance its two pipeline products, cirmtuzumab, an-anti ROR1 monoclonal antibody, and TK216, a small molecule that inhibits the biological activity of ets-family transcription factor oncoproteins.

INVESTOR CONTACT
James Breitmeyer
Oncternal Therapeutics, Inc. 
T: 858-434-1113 
E: jbreitmeyer@oncternal.com

MEDIA CONTACT
Ami Knoefler 
Spark BioComm 
T: 650-739-9952 
E: ami@sparkbiocomm.com

 

SOURCE Oncternal Therapeutics, Inc.

Creative Medical Technology Holdings Announces Initiation of In House Research Program at San Diego BioLabs

February 22, 2017 – 3:00 am

Clinical Stage Stem Cell Company Expands Translational Research Activities with Acceptance into Premier San Diego Research Facility

PHOENIX and SAN DIEGO, Feb. 22, 2017 /PRNewswire/ — Creative Medical Technology Holdings (the “Company”) (OTCQB:CELZ) announced today expansion of its translational research program using its AmnioStem universal donor stem cell product through establishment of laboratory facilities in San Diego.  The Company has initiated research activities at the San Diego BioLabs facility, a biotechnology incubator sponsored by the Pharmaceutical Companies, Boehringer Ingelheim, Novartis, and Sanofi.

In November 2016, the Company obtained an exclusive license from the University of California San Diego (UCSD) for issued patent #7,569,385 covering amniotic fluid derived stem cells1.  These stem cells, which are the basis for the Company’s AmnioStem product, have the unique ability to regenerate injured neurons after stroke and accelerate recovery in animal models.2,3  The Company intends to develop these cells as an “off the shelf” therapeutic product for stroke. 

“We believe that our ability to conduct in-house experimental research on these cells will position us to accelerate clinical translation and more effectively use the existing collaborative network that we have in place”, said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. “We are grateful for the team at BioLabs for having chosen us to join their exciting and forward-thinking group of biotechnology companies.”

As part of the in-house experimentation, scientists at Creative Medical Technology Holdings will be focused on: a) Supporting existing data and Investigational New Drug (IND) applications to the FDA; and, b) Assessing unconventional activities of the AmnioStem cell including immune modulatory and neurotrophic effects.

“Unlike other types of adult stem cells, in which the intellectual property space is very crowded, amniotic fluid stem cells represent an area open to new patent filings and novel uses of this cell type”, said Thomas Ichim, Ph.D., co-founder and Board Member of Creative Medical Technologies, Inc., the Company’s operating subsidiary. “By working with our external collaborators and our internal laboratory team, we plan to aggressively expand our patent portfolio in parallel to our clinical development plan.”

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a clinical stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.

Forward-Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.

Links to the reports listed below are a service to those interested in this information. While we believe these reports to be relevant and accurate, we do not endorse these reports and can make no guarantee as to their accuracy or completeness. Users visit the websites at their own risk.

1http://www.prnewswire.com/news-releases/creative-medical-technologies-receives-exclusive-license-to-key-amniotic-fluid-stem-cell-patent-from-university-of-california-system-300356233.html
2Tajiri et al. Therapeutic outcomes of transplantation of amniotic fluid-derived stem cells in experimental ischemic stroke. Front Cell Neurosci. 2014 Aug 13;8:227. http://journal.frontiersin.org/article/10.3389/fncel.2014.00227/full
3Tajiri et al. Intravenous grafts of amniotic fluid-derived stem cells induce endogenous cell proliferation and attenuate behavioral deficits in ischemic stroke rats. PLoS One. 2012;7(8):e43779.  http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043779

 

SOURCE Creative Medical Technology Holdings, Inc.

Associate Scientist, Molecular Biology – Celgene – San Diego, CA

February 21, 2017 – 9:40 pm

The successful candidate will utilize state-of-art biotechnology tools to define the underlying mechanism of response and resistance to novel cereblon…From Celgene – Wed, 22 Feb 2017 05:40:45 GMT – View all San Diego jobs

Technical Writer – TalentBurst, Inc. – San Diego, CA

February 21, 2017 – 8:13 pm

Quickly learn and apply new tools, processes, and standards. Three to five to years of experience as a technical writer, preferably in industry (software,…From TalentBurst, Inc. – Wed, 22 Feb 2017 04:13:24 GMT – View all San Diego jobs